Research programme: rare disease mRNA therapeutics - Elpidera

Drug Profile

Research programme: rare disease mRNA therapeutics - Elpidera

Alternative Names: Antibody messenger RNA therapeutics™; mRNA-3283; mRNA-3630; mRNA-3704; mRNA-3927; MT-004; MT-026; MT-033; MT-039; MT-059; MT-088; MT-104

Latest Information Update: 16 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Moderna Therapeutics
  • Developer Moderna Therapeutics; National Human Genome Research Institute
  • Class RNA
  • Mechanism of Action Alpha-galactosidase stimulants; Methylmalonyl CoA mutase stimulants; Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methylmalonic acidaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Fabry's disease; Methylmalonic acidaemia; Phenylketonuria
  • Research Acidaemia
  • No development reported Haemophilia

Most Recent Events

  • 11 Jul 2018 Preclinical trials in Fabry's disease in USA (Parenteral)
  • 11 Jul 2018 Preclinical trials in Phenylketonuria in USA (Parenteral)
  • 11 Jul 2018 mRNA 3704 receives Orphan Drug status for Methylmalonic acidaemia in Europe (Before July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top